☆ 4.6 Review

Progression in immunotherapy for advanced prostate cancer

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer

Tanya B. Dorff et al.

Summary: Immunotherapy has not achieved long-lasting remissions in advanced prostate cancer patients. More potent T-cell redirecting strategies are needed to overcome the immunologically exclusive and suppressive tumor microenvironment. This review provides an in-depth perspective on the various immunotherapy strategies currently under clinical investigation for men with advanced prostate cancer.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial

Swayamjeet Satapathy et al.

Summary: Lu-177-PSMA-617 has been shown to be safe and non-inferior to docetaxel in the treatment of mCRPC, suggesting it could be potentially used earlier in the disease course rather than solely reserved for advanced end-stage disease.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Multidisciplinary Sciences

GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas

Robbie G. Majzner et al.

Summary: Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are lethal pediatric tumors of the central nervous system. GD2-directed chimeric antigen receptor (CAR) T cells show promising preclinical efficacy. Four patients with H3K27M-mutated DIPG or spinal cord DMG were treated with GD2-CAR T cells and showed clinical and radiographic improvement.

NATURE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles et al.

Summary: Early clinical data suggest that some patients with castration-resistant prostate cancer may benefit from PD-L1 inhibition, especially with enzalutamide. However, a trial combining atezolizumab with enzalutamide did not improve overall survival in unselected patients. Genomic and immune biomarkers associated with response to immune checkpoint inhibitors were identified.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial

Nicholas J. Vogelzang et al.

Summary: In patients with metastatic castration-resistant prostate cancer, the combination of DCVAC/PCa and chemotherapy as maintenance treatment did not extend overall survival and was well tolerated.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up

James A. Eastham et al.

Summary: This article aims to provide clinicians with treatment guidelines for patients with clinically localized prostate cancer. Detailed statements on active surveillance, surgical management, and patient follow-up are provided. Continued research and publication of high-quality evidence are crucial for further improving care for these patients.

JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions

James A. Eastham et al.

Summary: This article summarizes the principles of radiation and future directions of study in patients with clinically localized prostate cancer. The guidelines aim to aid clinicians in the management of these patients.

JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design

Karim Fizazi et al.

Summary: Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension.

LANCET (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Xiangnan Guan et al.

Summary: Immune checkpoint blockade has revolutionized oncology by inducing durable anti-tumour immunity. In advanced prostate cancer patients, immunotherapy treatments have largely failed. However, inhibiting androgen receptor activity can increase the sensitivity of tumor-bearing hosts to checkpoint blockade therapy by enhancing CD8 T cell function and improving responsiveness to PD-1 targeted therapy.

NATURE (2022)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

CAR T cells reach clinical milestone in prostate cancer

Nicholas P. Tschernia et al.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Vivek Narayan et al.

Summary: CAR T cells show promising efficacy in hematologic malignancies, but face challenges in solid tumors due to the immunosuppressive tumor microenvironment. This study reports results from a phase 1 trial using engineered CAR T cells resistant to TGF-beta signaling in castration-resistant prostate cancer patients, showing both efficacy and dose-dependent toxicity. Future studies should explore multipronged approaches to improve outcomes in this setting.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Douglas G. McNeel et al.

Summary: The combination of programmed cell death 1 blockade and MVI-816 is safe and can enhance tumor-specific T cells, resulting in a favorable 6-month disease control rate. The occurrence of immune-related adverse events is significantly associated with prolonged time on treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Ryon P. Graf et al.

Summary: This study compared the treatment outcomes of immune checkpoint inhibitors (ICI) and taxane chemotherapy in mCRPC patients based on tumor mutational burden (TMB). The results showed that ICI was more effective than taxanes in patients with high TMB, but not in those with low TMB.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Oncology

Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs

Xiaokang Zhang et al.

Summary: This study investigates the combinative application of docetaxel and PSMA-CAR-T cells for the treatment of prostate cancer. The results demonstrate that this combination therapy can effectively inhibit the growth of prostate cancer cells in vitro and in vivo, potentially mitigating the adverse effects of chemotherapy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Urology & Nephrology

The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer

Yishen Wang et al.

Summary: This review discusses the current evidence for the use of prostate-specific membrane antigen (PSMA) PET and whole-body (WB) MRI in prostate cancer diagnosis and treatment. PSMA PET and WB MRI have been shown to have higher accuracy in detecting metastatic lesions and have potential in monitoring treatment response. However, more clinical trials are needed to determine their specific roles in patient management.

NATURE REVIEWS UROLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Karim Fizazi et al.

Summary: The study showed that nivolumab plus rucaparib is effective in patients with HRD-positive postchemotherapy or chemotherapy-naive mCRPC, especially those with BACA1/2 mutations. Safety profile was as expected with no new signals identified. It remains unclear whether the addition of nivolumab provides incremental improvements over rucaparib alone.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

Daniel Castellano et al.

Summary: This study conducted a systematic review to evaluate the clinical efficacy and safety of cabozantinib combination therapy for solid tumors. The results from randomized studies suggest that cabozantinib combined with other therapies may lead to improved progression-free survival in certain tumor types compared to current standards of care.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Michael J. Giffin et al.

Summary: AMG 757, a bispecific T-cell engager targeting DLL3, demonstrated potent antitumor activity in SCLC models, activating T cells and inducing significant tumor regression. It showed good tolerability in nonhuman primates and has the potential for intermittent administration in patients, suggesting it as a promising option for targeting DLL3-expressing SCLC tumors in clinical settings.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

Catherine H. Marshall et al.

Summary: The study aimed to investigate whether radium-223 enhances peripheral immune responses to sipuleucel-T in men with bone-predominant, minimally symptomatic metastatic castration-resistant prostate cancer. Results showed that patients receiving the combination treatment of sipuleucel-T and radium-223 were more likely to experience a PSA decline, as well as longer progression-free survival and overall survival.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Oncology

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer

May Daher et al.

Summary: CAR engineering has transformed the field of cellular therapy for cancer treatment by redirecting the specificity of immune effector cells. The use of natural killer (NK) cells as platforms for CAR engineering has emerged as a safe and effective alternative to traditional CAR-T cells. Expanding this strategy beyond T lymphocytes may lead to safer and more effective off-the-shelf cellular therapy products to combat cancer.

CANCER DISCOVERY (2021)

添加到收藏夹

Review Oncology

Exosome-based liquid biopsies in cancer: opportunities and challenges

W. Yu et al.

Summary: Liquid biopsy in cancer research has seen significant progress, with efforts focused on utilizing circulating tumor cells, circulating tumor DNA, and extracellular vesicles like exosomes. Exosomes, as part of the intercellular communication system, carry tumor-derived materials and can serve as stable biomarkers for early detection and monitoring of cancer.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Petra Deegen et al.

Summary: AMG 160, a bispecific T-cell engager immuno-oncology therapy targeting PSMA in mCRPC, demonstrates potent antitumor activity in vitro and in vivo. It shows enhanced cytotoxic activity when combined with diagnostic or therapeutic agents such as the PSMA-imaging agent, novel hormonal therapy, and immune checkpoint blockade. Preclinical data supports ongoing clinical evaluation in patients with mCRPC.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Editorial Material Oncology

BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers

Nikhil V. Kamat et al.

Summary: Targeting PSMA with AMG 160 shows promising preclinical efficacy in inducing T cell-driven cytolytic activity against prostate cancer, highlighting its potential therapeutic implications in immune oncology.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak et al.

Summary: Atezolizumab monotherapy showed good tolerability and evidence of disease control in patients with metastatic castration-resistant prostate cancer (mCRPC), albeit with limited efficacy. Further studies are needed to evaluate the potential benefits of combination therapy in this population.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on screening, diagnosis, and treatment of localized prostate cancer summarize the most recent recommendations for clinical practice, including risk-adapted strategies, medical imaging utilization, biopsy techniques, patient classification, and treatment options. Recommendations include consideration of moderate hypofractionation for intermediate-risk patients and a combination of local treatment with long-term hormonal therapy for cN1 PCa patients.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Immunology

Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings

Horst-Dieter Hummel et al.

Summary: The study reported the results of a first-in-human study of pasotuxizumab in patients with advanced castration-resistant prostate cancer. The data showed significant PSA response in some patients, suggesting the potential efficacy of this therapy in treating solid tumors.

IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines

Edward Schaeffer et al.

Summary: The NCCN Guidelines for Prostate Cancer provide recommendations for staging and risk assessment post-diagnosis, with management options for localized, regional, and metastatic disease. The guidelines also cover disease monitoring and treatment of recurrent disease. The NCCN Prostate Cancer Panel meets annually to update recommendations based on new clinical data, aiming to provide the most effective care for patients.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Medicine, General & Internal

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman et al.

Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.

LANCET (2021)

添加到收藏夹

News Item Biotechnology & Applied Microbiology

FDA approves fourth CAR-T cell therapy

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

Elise A. Chong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Ravi A. Madan et al.

Summary: This study evaluated the potential synergy of immunotherapy and enzalutamide in non-metastatic castration sensitive prostate cancer (nmCSPC), as well as the immunologic impact of enzalutamide on men with normal testosterone levels. Results showed that three months of enzalutamide without androgen deprivation therapy (ADT) induced significant PSA control and had an impact on immune profiles.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives

Jonas S. Heitmann et al.

Summary: Despite recent advances in cancer therapy with immunotherapy, there is still a lack of breakthrough for metastasized prostate carcinoma (PC) and T cell-based immunotherapeutic strategies have not been successfully established for PC treatment. Current focus is on the clinical development of bispecific antibodies (bsAbs) in the treatment of PC, with potential advantages over CAR-T cells, but challenges persist in achieving success in solid tumors.

CANCERS (2021)

添加到收藏夹

Article Oncology

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

D. J. McGrail et al.

Summary: Analysis of over 10,000 patient tumors from The Cancer Genome Atlas showed that TMB-H tumors had significantly higher response rates to immune checkpoint blockade in certain cancer types, while showing no significant benefit in others. These results do not support the use of TMB-H as a biomarker for ICB treatment across all solid cancer types, indicating the need for further tumor type-specific studies.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Cross-resistance and drug sequence in prostate cancer

Stefan A. J. Buck et al.

Summary: The expanding landscape of advanced prostate cancer treatment has seen the move of ARSIs and taxane chemotherapy to earlier stages, leading to the emergence of cross-resistance as a major challenge in current clinical practice. Understanding the mechanisms of cross-resistance is crucial in order to overcome this obstacle and improve treatment outcomes.

DRUG RESISTANCE UPDATES (2021)

添加到收藏夹

Review Oncology

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

Ignacio Melero et al.

Summary: Immunotherapies such as immune-checkpoint inhibitors and CAR T cells are transforming oncology and hematology, but systemic distribution poses safety concerns. Intratumoural delivery and tumour tissue-targeted compounds show promise in enhancing the efficacy of immunotherapies, with potential to induce abscopal or anenestic effects in preclinical models. Clinical trials evaluating these strategies face challenges related to administration methodology, pharmacokinetics, and response assessments.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Industrializing engineered autologous T cells as medicines for solid tumours

Cedrik M. Britten et al.

Summary: Cell therapy is a rapidly growing field in the pharmaceutical industry with significant therapeutic potential, particularly in the treatment of blood cancers. Despite success in this area, challenges remain in treating solid tumors. To fully industrialize engineered T cell therapies as mainstream medicines, they need to provide unique clinical effects and be applicable in currently unaddressed disease contexts.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Navigating CAR-T cells through the solid-tumour microenvironment

Andrew J. Hou et al.

Summary: CAR-T cells have limited efficacy in treating solid tumors, but various engineering strategies can overcome the obstacles posed by the tumor microenvironment, producing next-generation T cells with enhanced specificity and sustained effector function.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Oncology

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Meenal Sinha et al.

Summary: Combining CTLA-4 blockade with sipuleucel-T resulted in modest clinical activity. The timing of CTLA-4 blockade following sipuleucel-T did not alter antigen-specific responses. Clinical responses were associated with both lower baseline frequencies of CTLA-4 expressing T cells and a history of radiation therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Next Generation Sequencing Technology in the Clinic and Its Challenges

Lau K. Vestergaard et al.

Summary: This article highlights the importance of precise identification and annotation of mutations in clinical oncology, as well as the impact of sequencing technologies development and bioinformatic tools on the results. Genomic alterations are crucial in personalized medicine for treatment efficacy. Therefore, evaluating and validating bioinformatic pipelines, as well as vigilance towards different tools, are essential.

CANCERS (2021)

添加到收藏夹

Article Oncology

A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong et al.

Summary: This study evaluated the safety and efficacy of atezolizumab + radium-223 in men with mCRPC, showing that the combination therapy had greater toxicity than either drug alone, with no clear evidence of additional clinical benefit.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Daniel P. Petrylak et al.

Summary: Pembrolizumab has shown activity in mCRPC patients as monotherapy and in combination with docetaxel and prednisone/prednisolone. The Phase III KEYNOTE-921 study aims to evaluate the efficacy and safety of pembrolizumab plus docetaxel in mCRPC patients previously treated with an NHA therapy, addressing the unmet need for treatment options in this patient population.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Prostate cancer

Shahneen Sandhu et al.

Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.

LANCET (2021)

添加到收藏夹

Review Urology & Nephrology

The potential of CAR T cell therapy for prostate cancer

Philipp Wolf et al.

Summary: CAR T cell immunotherapy has shown clinical success in lymphoid malignancies but disappointing results in solid tumors. Improving CAR T cell therapy for prostate cancer could involve enhancing cell trafficking, overcoming the immunosuppressive tumor microenvironment, and enhancing cell persistence, specificity, and safety. Additionally, combining CAR T cell therapy with other treatments like androgen deprivation therapy, radiotherapy, or chemotherapy may increase efficacy and could also be applied as focal therapy for prostate cancer.

NATURE REVIEWS UROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer

Kai Shen et al.

Summary: PET/CT is widely used in prostate cancer, with F-18-FDG and Ga-68-PSMA as common tracers that have their own limitations and advantages. F-18-FDG has advantages in detecting local recurrence, visceral and lymph node metastases in partial progressive prostate cancer and castration-resistant prostate cancer patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Interleukins in cancer: from biology to therapy

Dania Briukhovetska et al.

Summary: This article provides an update on the role of interleukins in tumor biology, highlighting their significance in cancer development, progression, and immunotherapy. Interleukins can both promote cancer growth and enhance tumor-directed immune responses, making them a valuable target for improving treatment effectiveness and reducing side effects.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Review Immunology

Metabolic barriers to cancer immunotherapy

Kristin DePeaux et al.

Summary: The tumour microenvironment creates barriers that suppress immune responses, including physical barriers, recruitment of suppressive immune cells, and upregulation of inhibitory ligands on tumour cells. Therapies targeting metabolic restrictions in the tumour microenvironment show promise for combination therapies against various types of cancer.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Systemic immunity in cancer

Kamir J. Hiam-Galvez et al.

Summary: Understanding systemic immune landscape beyond the tumour microenvironment is crucial in assessing the effectiveness of immunotherapy in cancer treatment. Despite the potential of immunotherapy to induce new immune responses, compromised immune responses in individuals with tumors may limit its efficacy.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Oncology

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Revisiting Immunotherapy: A Focus on Prostate Cancer

Ha-Ram Cha et al.

CANCER RESEARCH (2020)

添加到收藏夹

Review Immunology

Top 10 Challenges in Cancer Immunotherapy

Priti S. Hegde et al.

IMMUNITY (2020)

添加到收藏夹

Review Oncology

The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types

Hermann Einsele et al.

CANCER (2020)

添加到收藏夹

Article Cell Biology

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Sumit K. Subudhi et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Houssein Abdul Sater et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Cell Biology

Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold

Kento Fujiwara et al.

CELLS (2020)

添加到收藏夹

Review Oncology

T cell-engaging therapies - BiTEs and beyond

Maria-Elisabeth Goebeler et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer

Christos E. Kyriakopoulos et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy

Mayassa J. Bou-Dargham et al.

BMC CANCER (2020)

添加到收藏夹

Review Oncology

Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes

Claps Melanie et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹

Review Immunology

Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer

Isabel Ben-Batalla et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Padmanee Sharma et al.

CANCER CELL (2020)

添加到收藏夹

Editorial Material Urology & Nephrology

Precision Oncology for Metastatic Prostate Cancer: Translation into Practice

Maria De Santis et al.

EUROPEAN UROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

Bianca Cioni et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Oncology

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Eric Powers et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Advanced Prostate Cancer: Treatment Advances and Future Directions

Umang Swami et al.

TRENDS IN CANCER (2020)

添加到收藏夹

Article Oncology

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

James L. Gulley et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer

Celestia S. Higano et al.

CANCER (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

Shiping Jiao et al.

CELL (2019)

添加到收藏夹

Review Oncology

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

K. M. Heinhuis et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

CAR-T cell therapy: a potential new strategy against prostate cancer

Giuseppe Schepisi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

Jianfeng Shen et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

Douglas G. McNeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

A. R. Hansen et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Manish R. Patel et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Chimeric Antigen Receptor Therapy

Carl H. June et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

CAR T cell immunotherapy for human cancer

Carl H. June et al.

SCIENCE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers

Daniel J. McGrail et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Review Oncology

CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment

Clare Y. Slaney et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial

Charles S. Fuchs et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

Ellen Wargowski et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Review Immunology

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma

Angela Rita Elia et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Review Oncology

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Ross A. Stewart et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories

Kyle J. Foreman et al.

LANCET (2018)

添加到收藏夹

Review Oncology

Targeted Alpha Therapy, an Emerging Class of Cancer Agents A Review

Christopher Parker et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis

Marie Christine Hupe et al.

FRONTIERS IN ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer

Jitka Fucikova et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Article Hematology

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Friederike Braig et al.

BLOOD (2017)

添加到收藏夹

Letter Oncology

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer

Philip W. Kantoff et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Jianjun Gao et al.

NATURE MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Akash Patnaik et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Review Oncology

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Elizabeth H. Stover et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew Smith et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Fred Saad et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Cell Biology

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

Yang Pu et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Article Oncology

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate

Michael T. Schweizer et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Julie N. Graff et al.

ONCOTARGET (2016)

添加到收藏夹

Article Medicine, General & Internal

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

J. Mateo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

Michal Podrazil et al.

ONCOTARGET (2015)

添加到收藏夹

Article Oncology

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Tomoe Higuchi et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Oncology

Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

Douglas G. McNeel et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Peter Hoskin et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

S. F. Slovin et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

David C. Smith et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

FDA Approves Radiopharmaceutical for Metastatic Prostate Cancer

Cancer Discovery (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells

Kosuke Yamamoto et al.

BIOCHEMICAL JOURNAL (2012)

添加到收藏夹

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Wilfred D. Stein et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Ipilimumab First Global Approval

Fiona Cameron et al.

DRUGS (2011)

添加到收藏夹

Article Oncology

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Philip W. Kantoff et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Sipuleucel-T

Celestia S. Higano et al.

NATURE REVIEWS DRUG DISCOVERY (2010)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Medicine, General & Internal

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.

Philip W. Kantoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

Chris Tran et al.

SCIENCE (2009)

添加到收藏夹

Article Oncology

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

Ravi A. Madan et al.

CLINICAL CANCER RESEARCH (2008)

添加到收藏夹

Article Endocrinology & Metabolism

Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level

K. Radojevic et al.

JOURNAL OF ENDOCRINOLOGY (2007)

添加到收藏夹

Article Oncology

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

Eric J. Small et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

HD Dong et al.

NATURE MEDICINE (2002)

添加到收藏夹

Article Biochemistry & Molecular Biology

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

Z Gu et al.

ONCOGENE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.